

# Speaker's Biosketch

ICoLA 2024

## **Andre Zimmerman (Harvard Medical School/TIMI Study Group, USA)**

Andre Zimmerman, MD, PhD, is a Preventive Cardiologist and Head of the Clinical Trials Unit - Academic Research Organization at Hospital Moinhos de Vento (HMV-Brazil), an academic institution from Porto Alegre, Brazil. He received his medical degree at the Federal University of Rio Grande do Sul (Brazil), his PhD (*summa cum laude*) in Cardiology at the same institution, and completed his postgraduate training in clinical research at the Brazilian Clinical Research Institute. Dr. Zimmerman has been awarded grants by the Lemann Foundation and the Brazilian Ministry of Education for research and international studies. Prior to his position at HMV-Brazil, Dr. Zimmerman completed his Postdoctoral Fellowship at the TIMI Study Group, Brigham and Women's Hospital (United States) between 2022 and 2024, focusing on large-scale clinical trials in cardiovascular medicine. His primary research interest is studying the effect of novel triglyceride-lowering therapies. Contributions to the field include analyses and conduction of phase 2-3 clinical trials of RNA-based therapies targeting ANGPTL3 (vupanorsen) and ApoC-III (olezarsen) in patients with hypertriglyceridemia.